Evidence map›Paper›PMID 33609591›Full record

Observational studyInternational journal of radiation oncology, biology, physics2021

Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot.

Roger Sun, Samir Achkar, Samy Ammari, Sophie Bockel, Emmanuelle Gallois, Arnaud Bayle, Enzo Battistella, Flore Salviat, Mansouria Merad, Adrien Laville and 8 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Roger SunDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.
Samir AchkarDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Samy AmmariDepartment of Radiology, Gustave Roussy, Paris-Saclay University, Villejuif, France; BioMaps (UMR1281), Université Paris-Saclay, CNRS, INSERM, CEA, Orsay and Gustave Roussy, Villejuif, France.
Sophie BockelDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Emmanuelle GalloisDepartment of Biopathology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Arnaud BayleDepartment of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Enzo BattistellaRadiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.
Flore SalviatDepartment of Biostatistics, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Mansouria MeradDepartment of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Adrien LavilleDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Kanta KaDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Franck GriscelliDepartment of Biopathology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Laurence AlbigesDepartment of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Fabrice BarlesiDepartment of Cancer Medicine, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Alberto BossiDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Sofia RiveraDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Cyrus ChargariDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France.
Eric DeutschDepartment of Radiation Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France; Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Gustave Roussy, Villejuif, France. Electronic address: eric.deutsch@gustaveroussy.fr.
Institut Gustave Roussy · FRRadiothérapie Moléculaire et Innovation ThérapeutiqueUniversité Paris-Saclay · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients with cancer are presumed to be more vulnerable to COVID-19. We evaluated a screening strategy combining chest computed tomography (CT) and reverse-transcription polymerase chain reaction (RT-PCR) for patients treated with radiation therapy at our cancer center located in a COVID-19 French hotspot during the first wave of the pandemic. METHODS AND MATERIALS: Chest CT images were proposed during radiation therapy CT simulation. Images were reviewed by an expert radiologist according to the COVID-19 Reporting and Data System classification. Nasal swabs with RT-PCR assay were initially proposed in cases of suspicious imaging or clinical context and were eventually integrated into the systematic screening. A dedicated radiation therapy workflow was proposed for COVID-19 patients to limit the risk of contamination.

resultsFrom March 18, 2020 to May 1, 2020, 480 patients were screened by chest CT, and 313 patients had both chest CT and RT-PCR (65%). The cumulative incidence of COVID-19 was 5.4% (95% confidence interval [CI], 3.6-7.8; 26 of 480 patients). Diagnosis of COVID-19 was made before radiation therapy for 22 patients (84.6%) and during RT for 4 patients (15.3%). Chest CT directly aided the diagnosis of 7 cases in which the initial RT-PCR was negative or not feasible, out of a total of 480 patients (1.5%) and 517 chest CT acquisitions. Four patients with COVID-19 at the time of the chest CT screening had a false negative CT. Sensitivity and specificity of chest CT screening in patients with both RT-PCR and chest CT testing were estimated at 0.82 (95% CI, 0.60-0.95) and 0.98 (95% CI, 0.96-0.99), respectively. Adaptation of the radiation therapy treatment was made for all patients, with 7 postponed treatments (median: 5 days; interquartile range, 1.5-14.8).

conclusionsThe benefit of systematic use of chest CT screening during CT simulation for patients undergoing radiation therapy during the COVID-19 pandemic seemed limited.

Indexed as

COVID-19 Nucleic Acid TestingMultidetector Computed TomographyAdolescentAdultAgedCancer Care FacilitiesChildConfidence IntervalsCOVID-19FemaleFranceHumansIncidenceMaleMiddle AgedNeoplasms

Identifiers

PMID33609591
PMCPMC7887448
OpenAlexW3129557247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.